

**REMARKS**

This amendment was filed to properly represent the changes in claims 40 and 48 from previously filed amendments as requested by the examiner in the Office Communication mailed May 2, 2003. Claims 40-43, 48-52 and new claims 58-59 are now pending in this application.

Applicants believe that the present application is now in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date June 2, 2003

FOLEY & LARDNER  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5143  
Telephone: (202) 672-5571  
Facsimile: (202) 672-5399

By Harold C. Wegner Reg. No. 35,264  
for Harold C. Wegner  
Attorney for Applicants  
Registration No. 25,258

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 19-0741 for any such fees; and applicant(s) hereby petition for any needed extension of time.

Below is the marked up version showing changes to the claim(s):

40. **(Amended)** A method for making a reshaped human antibody comprising:

**(a) providing** complementary determining regions derived from a mouse antibody and framework regions derived from a human antibody, [wherein]

**(b) substituting** an amino acid residue of position 46 of an L chain numbered according to Kabat [et al.] is a mouse antibody residue and the reshaped human antibody creates a functional antigen binding site, **and**

**(c) substituting 0-5 amino acid residue(s) on an H chain numbered according to Kabat, with a mouse antigen binding site.**

48. **(Amended)** A method for making a single-chain Fv region comprising:

**(a) producing** a reshaped antibody [H chain V region and L chain V region, which are linked] by **substituting an amino acid residue on position 46 of an L chain V region numbered according to Kabat, as a mouse antigen binding site and by substitution 0-5 amino acids on the H chain V region, numbered according to Kabat, with a mouse antigen binding site,**

**(b) linking the L chain V region and the H chain V region with** a linker peptide, and [have] *derived*

**(c) combining identified** complementary determining regions from a mouse antibody and framework regions derived from a human antibody, wherein an amino acid residue 46 of L chain V region numbered according to Kabat [et al.] is a mouse residue and the single chain Fv region creates a functional antigen binding site.